By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Pentobarbital (monograph)
Drugs

Pentobarbital (monograph)

https://themeditary.com/drug/pentobarbital-monograph-7022.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Aug 15, 2023  Additional Content by TheMediTary.Com

Generic name: nembutal

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Nembutal sodium (injection), Pentobarbital (injection)

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Pentobarbital (monograph)?

Warning

Special Alerts:

A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].

Introduction

Barbiturate; anxiolytic, sedative, hypnotic, and anticonvulsant.

Uses for Pentobarbital

Insomnia

Short-term treatment of insomnia (i.e., ≤2 weeks duration); decreased effectiveness for sleep induction and maintenance after 2 weeks.

Has been used for routine sedation. However, barbiturates used infrequently for this indication since there are few clinical situations in which oral barbiturates provide a safety or efficacy advantage over nonbarbiturate sedatives/hypnotics.

Surgery and Preanesthesia

Preoperatively, to produce sedation and relieve anxiety.

Provide basal hypnosis for general, spinal, or regional anesthesia, or to facilitate intubation procedures.

Seizure Disorders

Alternate therapy to control status epilepticus or acute seizure episodes resulting from meningitis, poisons, eclampsia, alcohol withdrawal, tetanus, or chorea.

IV diazepam generally considered drug of choice for termination of status epilepticus.

Drug Withdrawal

Withdrawal of barbiturate or nonbarbiturate hypnotics in physically dependent patients.

Agitated Behavior

Has been used to control acute episodes of agitated behavior in psychoses† [off-label]; however, little value in long-term management of psychoses.

Coma Induction

Has been used in high doses to induce coma in the management of cerebral ischemia† [off-label] and increased intracranial pressure† [off-label] associated with head trauma, stroke, Reye’s syndrome, cardiac arrest, asphyxiation, or drowning.

Has been used to ameliorate or prevent sequelae associated with cerebral ischemia during neurosurgical procedures† [off-label] that require long periods of cerebral hypoxia.

Related/similar drugs

trazodone, hydroxyzine, lorazepam, diazepam, Ativan, promethazine, fentanyl

Pentobarbital Dosage and Administration

General

  • Adjust dosage carefully and slowly according to individual requirements and response.

  • Following chronic administration, withdraw pentobarbital slowly to avoid the possibility of precipitating withdrawal symptoms if the patient is physically dependent on the drug.

  • To prevent rebound in rapid eye movement (REM) sleep, withdrawal of a single therapeutic dose over 5 or 6 days (e.g., reducing dosage from 3 to 2 doses daily for 1 week) has been recommended when barbiturates are discontinued following prolonged use.

Insomnia

  • Do not administer for periods >2 weeks.

Administration

Administer by IM or slow IV injection.

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Reserve IV administration for inducing anesthesia or emergency treatment of acute seizure episodes or acute episodes of agitated behavior in psychoses. (See Seizure Disordersand also Agitated Behavior under Uses.)

Usually administered in a concentration of 50 mg/mL.

Must be administered by slow IV injection and in fractional doses to allow for adequate time for pentobarbital to distribute into CNS. A time interval of ≥1 minute is required to determine the full effect of an IV dose.

Administer under close supervision and in a setting where vital signs can be monitored; BP, respiration, and cardiac function maintained; and equipment for resuscitation and artificial ventilation are readily available. (See Respiratory and Cardiovascular Effects under Cautions.)

Avoid intra-arterial and extravascular injection. (See Intra-arterial Injection under Cautions.)

Rate of Administration

Do not exceed 50 mg/minute. (See Respiratory and Cardiovascular Effects under Cautions.)

IM Administration

Administer by deep IM injection into a large muscle.

Administer a maximum volume of 5 mL at any one site to avoid tissue irritation.

After administration of large hypnotic doses, observe patient closely for 20–30 minutes and monitor vital signs to ensure narcosis will not be excessive.

Dosage

Available as pentobarbital sodium; dosage expressed in terms of the salt.

IV dosage generally determined by patient’s reaction to slow administration of the drug.

A time interval of >1 minute required to determine the full effect of an IV dose.

Pediatric Patients

Insomnia
IM

2–6 mg/kg or 125 mg/m2 as a single dose (maximum 100 mg).

Surgery and Preanesthesia
IM

Usually, approximately 5 mg/kg.

IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Seizure Disorders
IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Agitated Behavior† [off-label]
IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Adults

Insomnia
IM

150–200 mg as a single dose.

IV

Initially, usually 100 mg for an adult weighing 70 kg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Surgery and Preanesthesia
IM

150–200 mg as a single dose.

Seizures
IV

Initially, usually 100 mg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Administer minimum dosage to avoid compounding the CNS and respiratory depression which may follow seizures. (See CNS Depression and also Respiratory and Cardiovascular Effects, under Cautions.)

Drug Withdrawal
IM

Establish a stabilizing dose (generally adminstered at 6-hour intervals), then decrease the daily dose by no more than 100 mg per day. Severely dependent patients can usually be withdrawn from barbiturates in 14–21 days.

Agitated Behavior†
IV

Initially, usually 100 mg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Prescribing Limits

Pediatric Patients

Insomnia
IM

Maximum 100 mg daily.

Adults

IV

Maximum 200–500 mg.

Special Populations

Hepatic Impairment

Dosage reduction recommended.

Renal Impairment

Dosage reduction recommended.

Geriatric Patients

Dosage reduction recommended.

Debilitated Patients

Dosage reduction recommended.

Detailed Pentobarbital dosage information

Warnings

Contraindications

  • Known hypersensitivity to any barbiturates.

  • History of manifest or latent porphyria. (See Porphyria under Cautions.)

  • Bronchopneumonia or other severe pulmonary insufficiency.

Warnings/Precautions

Warnings

Pain Reaction

Potential for paradoxical excitement and/or euphoria, restlessness, or delirium in patients with severe pain. Barbiturates could mask important symptoms in patients with acute or chronic pain. Use with caution in such patients. Should not be used in the presence of uncontrolled pain.

Abuse Potential

Possible tolerance, psychological dependence, and physical dependence following prolonged administration.

Withdrawal Effects

Abrupt cessation after prolonged use in dependent individuals may result in withdrawal symptoms (e.g., delirium, convulsions) and potentially be fatal. Drug must be withdrawn gradually in patients receiving excessive dosages over extended periods of time.

CNS Depression

Performance of activities requiring mental alertness or physical coordination may be impaired.

Concurrent use of other CNS depressants may potentiate CNS depression. (See Specific Drugs under Interactions.)

Respiratory and Cardiovascular Effects

Possible respiratory depression, apnea, laryngospasm, or vasodilation and hypotension, particularly if pentobarbital is administered IV too rapidly. Administer slowly; personnel and equipment should be readily available for administration of artificial respiration.

Fetal/Neonatal Morbidity

May cause fetal harm. If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.

Retrospective, case-controlled studies indicate an association between maternal ingestion of barbiturates and a higher than expected incidence of fetal abnormalities.

Based on animal data, repeated or prolonged use of general anesthetics and sedation drugs, including pentobarbital, during the third trimester of pregnancy may result in adverse neurodevelopmental effects in the fetus. (See Pediatric Use under Cautions and also see Advice to Patients.)

Barbiturates have caused postpartum hemorrhage and hemorrhagic disease in neonates; readily reversible with vitamin K therapy.

Possible withdrawal symptoms in neonates born to women who received barbiturates throughout the last trimester of pregnancy. Premature neonates are particularly susceptible to the depressant effects of barbiturates.

Porphyria

Potential exacerbation of acute intermittent porphyria or porphyria variegata. (See Contraindications under Cautions.)

Complex Sleep-related Behaviors

Potential risk of complex sleep-related behaviors such as sleep-driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), making phone calls, or preparing and eating food, while asleep.

Sensitivity Reactions

Potential risk of anaphylaxis and angioedema; may occur as early as with the first dose of drug.

Dermatologic Effects and Hypersensitivity Reactions

Exfoliative dermatitis (e.g., Stevens-Johnson syndrome), sometimes fatal, reported rarely. Because skin eruptions can precede potentially fatal reactions, discontinue pentobarbital whenever dermatologic reactions occur.

General Precautions

Intra-arterial Injection

Inadvertent intra-arterial administration can cause local reactions varying in severity from transient pain to gangrene. Inadvertent extravascular injection may cause local tissue damage and result in necrosis.

Discontinue injection if the patient complains of pain in limb.

Suicide

Use with caution, if at all, in patients with depression or suicidal tendencies.

Concomitant Diseases

Use parenterally with caution in patients with hypertension, hypotension, pulmonary or cardiovascular disease, or shock.

Specific Populations

Pregnancy

Category D. (See Fetal/Neonatal Morbidity under Cautions.)

Lactation

Distributed into milk; use with caution.

Pediatric Use

Repeated or prolonged use of general anesthetics and sedation drugs, including pentobarbital, in children <3 years of age or during the third trimester of pregnancy may adversely affect neurodevelopment. In animals, use for >3 hours of anesthetic and sedation drugs that block N-methyl-d-aspartic acid (NMDA) receptors and/or potentiate GABA activity leads to widespread neuronal apoptosis in the brain and long-term deficits in cognition and behavior; clinical relevance to humans is unknown.

Some evidence suggests similar deficits may occur in children following repeated or prolonged exposure to anesthesia early in life. Some evidence also indicates that a single, relatively brief exposure to general anesthesia in generally healthy children is unlikely to cause clinically detectable deficits in global cognitive function or serious behavioral disorders. Most studies to date have substantial limitations; further research needed to fully characterize effects, particularly for prolonged or repeated exposures and in more vulnerable populations (e.g., less healthy children).

Consider benefits and potential risks when determining the timing of elective procedures requiring anesthesia. FDA states that medically necessary procedures should not be delayed or avoided. (See Advice to Patients.)

Geriatric Use

Possible increased sensitivity to barbiturates. Geriatric patients may frequently react to barbiturates with excitement, confusion, or depression.

Debilitated Patients

Possible increased sensitivity to barbiturates. Debilitated patients may frequently react to barbiturates with excitement, confusion, or depression.

Hepatic Impairment

Use with caution; should not be used in patients with marked hepatic impairment, including patients with premonitory signs of hepatic coma.

Common Adverse Effects

Residual sedation, drowsiness, lethargy, vertigo, nausea, vomiting, headache.

How should I use Pentobarbital (monograph)

General

  • Adjust dosage carefully and slowly according to individual requirements and response.

  • Following chronic administration, withdraw pentobarbital slowly to avoid the possibility of precipitating withdrawal symptoms if the patient is physically dependent on the drug.

  • To prevent rebound in rapid eye movement (REM) sleep, withdrawal of a single therapeutic dose over 5 or 6 days (e.g., reducing dosage from 3 to 2 doses daily for 1 week) has been recommended when barbiturates are discontinued following prolonged use.

Insomnia

  • Do not administer for periods >2 weeks.

Administration

Administer by IM or slow IV injection.

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Reserve IV administration for inducing anesthesia or emergency treatment of acute seizure episodes or acute episodes of agitated behavior in psychoses. (See Seizure Disordersand also Agitated Behavior under Uses.)

Usually administered in a concentration of 50 mg/mL.

Must be administered by slow IV injection and in fractional doses to allow for adequate time for pentobarbital to distribute into CNS. A time interval of ≥1 minute is required to determine the full effect of an IV dose.

Administer under close supervision and in a setting where vital signs can be monitored; BP, respiration, and cardiac function maintained; and equipment for resuscitation and artificial ventilation are readily available. (See Respiratory and Cardiovascular Effects under Cautions.)

Avoid intra-arterial and extravascular injection. (See Intra-arterial Injection under Cautions.)

Rate of Administration

Do not exceed 50 mg/minute. (See Respiratory and Cardiovascular Effects under Cautions.)

IM Administration

Administer by deep IM injection into a large muscle.

Administer a maximum volume of 5 mL at any one site to avoid tissue irritation.

After administration of large hypnotic doses, observe patient closely for 20–30 minutes and monitor vital signs to ensure narcosis will not be excessive.

Dosage

Available as pentobarbital sodium; dosage expressed in terms of the salt.

IV dosage generally determined by patient’s reaction to slow administration of the drug.

A time interval of >1 minute required to determine the full effect of an IV dose.

Pediatric Patients

Insomnia
IM

2–6 mg/kg or 125 mg/m2 as a single dose (maximum 100 mg).

Surgery and Preanesthesia
IM

Usually, approximately 5 mg/kg.

IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Seizure Disorders
IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Agitated Behavior† [off-label]
IV

Initially, usually 50 mg. If necessary, administer subsequent doses after >1 minute.

Adults

Insomnia
IM

150–200 mg as a single dose.

IV

Initially, usually 100 mg for an adult weighing 70 kg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Surgery and Preanesthesia
IM

150–200 mg as a single dose.

Seizures
IV

Initially, usually 100 mg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Administer minimum dosage to avoid compounding the CNS and respiratory depression which may follow seizures. (See CNS Depression and also Respiratory and Cardiovascular Effects, under Cautions.)

Drug Withdrawal
IM

Establish a stabilizing dose (generally adminstered at 6-hour intervals), then decrease the daily dose by no more than 100 mg per day. Severely dependent patients can usually be withdrawn from barbiturates in 14–21 days.

Agitated Behavior†
IV

Initially, usually 100 mg. After >1 minute, if necessary, administer additional small doses up to a total of 200–500 mg.

Prescribing Limits

Pediatric Patients

Insomnia
IM

Maximum 100 mg daily.

Adults

IV

Maximum 200–500 mg.

Special Populations

Hepatic Impairment

Dosage reduction recommended.

Renal Impairment

Dosage reduction recommended.

Geriatric Patients

Dosage reduction recommended.

Debilitated Patients

Dosage reduction recommended.

Detailed Pentobarbital dosage information
Pentobarbital (monograph) Dosage information (more detail)

What other drugs will affect Pentobarbital (monograph)?

Metabolized by hepatic microsomal enzymes. Induces hepatic microsomal enzymes.

Specific Drugs

Drug

Interaction

Comments

Anticoagulants, oral (e.g., warfarin)

Possible decreased plasma warfarin concentrations

Adjust anticoagulant dosage as necessary, especially upon initiation or discontinuance of pentobarbital

CNS depressants (e.g., sedatives, hypnotics, antihistamines, tranquilizers, alcohol)

Possible additive depressant effects

Contraceptives, oral

Possible enhanced metabolism of estrogenic and progestinic components; potential for decreased oral contraceptive effectiveness and increased risk of pregnancy with pentobarbital pretreatment or concurrent therapy

Consider alternate methods of contraception

Corticosteroids

Possible increased corticosteroid metabolism

Dosage adjustment of corticosteroid may be required; closely monitor patients (especially asthmatics) receiving corticosteroids when pentobarbital is initiated

Doxycycline

Possible decreased half-life of doxycycline; effect may persist up to 2 weeks after discontinuance of pentobarbital

If possible, avoid concomitant administration; if administered concomitantly, monitor clinical response to doxycycline

Griseofulvin

Possible decreased griseofulvin absorption, resulting in decreased blood concentrations

Avoid concomitant administration; if concomitant therapy is necessary, administration of griseofulvin in 3 divided doses daily may improve absorption

Monitor blood griseofulvin concentrations and increase dosage, if necessary

MAO inhibitors

Possible prolongation of pentobarbital effects

Dose adjustment of pentobarbital may be required

Phenytoin

Increased, decreased, or no change in plasma phenytoin concentrations reported

Monitor plasma concentrations of phenytoin and pentobarbital; adjust dosages as necessary

Valproic acid

Possible increased plasma pentobarbital concentrations

Monitor plasma pentobarbital concentrations and adjust dosage as needed

More about Pentobarbital (monograph) (Nembutal)

Dosage information
Pentobarbital (monograph) Side Effects
During pregnancy
Pentobarbital Sodium Injection Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Patient resources

Pentobarbital

Related treatment guides

Sedation
Insomnia
Status Epilepticus
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by